|
1
|
Tan N, Wu H, Cao M, Yang F, Yan X, He S,
Cao M, Zhang S, Teng Y, Li Q, et al: Global, regional, and national
burden of early-onset gastric cancer. Cancer Biol Med. 21:667–678.
2024.PubMed/NCBI
|
|
2
|
Yu WY, Li X, Zhu J, Ding YM, Tao HQ and Du
LB: Epidemiological characteristics of gastric cancer in China and
worldwide. Zhonghua Zhong Liu Za Zhi. 47:468–476. 2025.(In
Chinese). PubMed/NCBI
|
|
3
|
Lin JL, Lin JX, Lin GT, Huang CM, Zheng
CH, Xie JW, Wang JB, Lu J, Chen QY and Li P: Global incidence and
mortality trends of gastric cancer and predicted mortality of
gastric cancer by 2035. BMC Public Health. 24:17632024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma ES, Wang ZX, Zhu MQ and Zhao J: Immune
evasion mechanisms and therapeutic strategies in gastric cancer.
World J Gastrointest Oncol. 14:216–229. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Li C, Lu Y, Liu C and Yang W: Tumor
microenvironment-mediated immune tolerance in development and
treatment of gastric cancer. Front Immunol. 13:10168172022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yasuda T and Wang YA: Gastric cancer
immunosuppressive microenvironment heterogeneity: Implications for
therapy development. Trends Cancer. 10:627–642. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romagnani S: Immunological tolerance and
autoimmunity. Intern Emerg Med. 1:187–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang H, Dai Z, Wu W, Wang Z, Zhang N,
Zhang L, Zeng WJ, Liu Z and Cheng Q: Regulatory mechanisms of
immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer
Res. 40:1842021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Liu T, Huang T, Shang M and Wang
X: The mechanisms on evasion of anti-tumor immune responses in
gastric cancer. Front Oncol. 12:9438062022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi AN, Zhou YB and Wang GH:
Immunotherapy: Progress and challenges of a revolutionary treatment
for gastric cancer. Zhonghua Wai Ke Za Zhi. 63:563–567. 2025.(In
Chinese). PubMed/NCBI
|
|
11
|
Zhao Y, Bai Y, Shen M and Li Y:
Therapeutic strategies for gastric cancer targeting immune cells:
Future directions. Front Immunol. 13:9927622022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He B, Wood KH, Li ZJ, Ermer JA, Li J,
Bastow ER, Sakaram S, Darcy PK, Spalding LJ, Redfern CT, et al:
Selective tubulin-binding drugs induce pericyte phenotype switching
and anti-cancer immunity. EMBO Mol Med. 17:1071–1100. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang K, Xie CJ, Ding Z, Shan T, Zhong Z,
Yuan FL, Wu JJ, Yuan ZD, Qian C, Yu L, et al: PDE5A+
cancer-associated fibroblasts enhance immune suppression in gastric
cancer. Gut. October 20–2025.(Epub ahead of print). View Article : Google Scholar
|
|
14
|
Shaibu Z, Danbala IA, Chen Z and Zhu W:
Role of mesenchymal stem cells in modulating cytokine networks and
immune checkpoints in gastric cancer therapy. Biochim Biophys Acta
Rev Cancer. 1880:1894332025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He X, Guan XY and Li Y: Clinical
significance of the tumor microenvironment on immune tolerance in
gastric cancer. Front Immunol. 16:15326052025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lv Y, Zhao Y, Wang X, Chen N, Mao F, Teng
Y, Wang T, Peng L, Zhang J, Cheng P, et al: Increased intratumoral
mast cells foster immune suppression and gastric cancer progression
through TNF-α-PD-L1 pathway. J Immunother Cancer. 7:542019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weng N, Zhou C, Zhou Y, Zhong Y, Jia Z,
Rao X, Qiu H, Zeng G, Jin X, Zhang J, et al: IKZF4/NONO-RAB11FIP3
axis promotes immune evasion in gastric cancer via facilitating
PD-L1 endosome recycling. Cancer Lett. 584:2166182024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shukla A, Cloutier M, Appiya Santharam M,
Ramanathan S and Ilangumaran S: The MHC Class-I Transactivator
NLRC5: Implications to cancer immunology and potential applications
to cancer immunotherapy. Int J Mol Sci. 22:19642021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Yu D, Ji C, Wang M, Fu M, Qian Y
and Zhang X, Ji R, Li C, Gu J and Zhang X: Exosomal
miR-4745-5p/3911 from N2-polarized tumor-associated neutrophils
promotes gastric cancer metastasis by regulating SLIT2. Mol Cancer.
23:1982024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nair R, Somasundaram V, Kuriakose A,
Krishn SR, Raben D, Salazar R and Nair P: Deciphering T-cell
exhaustion in the tumor microenvironment: Paving the way for
innovative solid tumor therapies. Front Immunol. 16:15482342025.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chow A, Perica K, Klebanoff CA and Wolchok
JD: Clinical implications of T cell exhaustion for cancer
immunotherapy. Nat Rev Clin Oncol. 19:775–790. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu K, Cao Y, Zhang Z, Wang L, Gu Y, Xu T,
Zhang X, Guo X, Shen Z and Qin J: Blockade of CLEVER-1 restrains
immune evasion and enhances anti-PD-1 immunotherapy in gastric
cancer. J Immunother Cancer. 13:e0110802025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi T, Zhang Y, Wang Y, Song X, Wang H,
Zhou X, Liang K, Luo Y, Che K, Wang X, et al: DKK1 promotes tumor
immune evasion and impedes Anti-PD-1 treatment by inducing
immunosuppressive macrophages in gastric cancer. Cancer Immunol
Res. 10:1506–1524. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang T, Li Y, Zhai E, Zhao R, Qian Y,
Huang Z, Liu Y, Zhao Z, Xu X, Liu J, et al: Intratumoral
fusobacterium nucleatum recruits Tumor-associated neutrophils to
promote gastric cancer progression and immune evasion. Cancer Res.
85:1819–1841. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Zhang W, Bai J, Li J and Li H:
Emerging role of helicobacter pylori in the immune evasion
mechanism of gastric cancer: An insight into tumor
microenvironment-Pathogen interaction. Front Oncol. 12:8624622022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang L, Zhao X, Li Y, Hu Y, Sun Y, Liu S,
Zhang Z, Li Y, Feng X, Yuan J, et al: The tumor immune
microenvironment remodeling and response to HER2-targeted therapy
in HER2-positive advanced gastric cancer. IUBMB Life. 76:420–436.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun H, Wang X, Wang X, Xu M and Sheng W:
The role of cancer-associated fibroblasts in tumorigenesis of
gastric cancer. Cell Death Dis. 13:8742022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Allam A, Yakou M, Pang L, Ernst M and
Huynh J: Exploiting the STAT3 nexus in cancer-associated
fibroblasts to improve cancer therapy. Front Immunol.
12:7679392021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X,
Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated
fibroblasts promotes epithelial-mesenchymal transition and
metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Oncotarget. 8:20741–20750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hilmi M, Nicolle R, Bousquet C and
Neuzillet C: Cancer-associated fibroblasts: Accomplices in the
tumor immune evasion. Cancers (Basel). 12:29692020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Avagliano A, Granato G, Ruocco MR, Romano
V, Belviso I, Carfora A, Montagnani S and Arcucci A: Metabolic
reprogramming of cancer associated fibroblasts: The slavery of
stromal fibroblasts. Biomed Res Int. 2018:60754032018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kitamura F, Semba T, Yasuda-Yoshihara N,
Yamada K, Nishimura A, Yamasaki J, Nagano O, Yasuda T, Yonemura A,
Tong Y, et al: Cancer-associated fibroblasts reuse cancer-derived
lactate to maintain a fibrotic and immunosuppressive
microenvironment in pancreatic cancer. JCI Insight. 8:e1630222023.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iha K, Sato A, Tsai HY, Sonoda H, Watabe
S, Yoshimura T, Lin MW and Ito E: Gastric cancer cell-derived
exosomal GRP78 enhances angiogenesis upon stimulation of vascular
endothelial cells. Curr Issues Mol Biol. 44:6145–6157. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang R, Liu G, Wang K, Pan Z, Pei Z and Hu
X: Hypoxia signature derived from tumor-associated endothelial
cells predict prognosis in gastric cancer. Front Cell Dev Biol.
13:15156812025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fang J, Lu Y, Zheng J, Jiang X, Shen H,
Shang X, Lu Y and Fu P: Exploring the crosstalk between endothelial
cells, immune cells, and immune checkpoints in the tumor
microenvironment: New insights and therapeutic implications. Cell
Death Dis. 14:5862023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Q, Yu M, Lin Z, Wu L, Xia P, Zhu M,
Huang B, Wu W, Zhang R, Li K, et al: COL1A1-positive endothelial
cells promote gastric cancer progression via the ANGPTL4-SDC4 axis
driven by endothelial-to-mesenchymal transition. Cancer Lett.
623:2177312025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu Y, Xiang M, Brulois KF, Lazarus NH,
Pan J and Butcher EC: Endothelial cell Notch signaling programs
cancer-associated fibroblasts to promote tumor immune evasion. Res
Sq. Jun 11–2024.doi: 10.21203/rs.3.rs-4538031/v1.
|
|
38
|
Xu Y, Miller CP, Tykodi SS, Akilesh S and
Warren EH: Signaling crosstalk between tumor endothelial cells and
immune cells in the microenvironment of solid tumors. Front Cell
Dev Biol. 12:13871982024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang Y, Xu X, Lu Y, Sun Q, Zhang L, Shao
J, Chen D, Chang Y, Sun X, Zhuo W and Zhou T: The phase separation
of extracellular matrix protein matrilin-3 from cancer-associated
fibroblasts contributes to gastric cancer invasion. FASEB J.
38:e234062024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ji L, Peng J, Lin Y, Zhong Y, Ni B, Zhu C
and Zhang Z: High extracellular matrix stiffness upregulates TNNT1
to awaken dormant tumor cells in liver metastatic niches of gastric
cancer. Cell Oncol (Dordr). 48:815–834. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li S, Sampson C, Liu C, Piao HL and Liu
HX: Integrin signaling in cancer: Bidirectional mechanisms and
therapeutic opportunities. Cell Commun Signal. 21:2662023.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zaheer J, Shanmugiah J, Kim S, Kim H and
Kim JS: Tumor microenvironment modulation by SERPINE1 increases
radioimmunotherapy in murine model of gastric cancer. Sci Rep.
15:164492025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qian X, Jia W, Li Y, Chen J, Zhang J and
Sun Y: COL4A1 promotes gastric cancer progression by regulating
tumor invasion, tumor microenvironment and drug sensitivity. Curr
Med Chem. Apr 7–2025.doi: 10.2174/0109298673351943250314074632
(Epub ahead of print). View Article : Google Scholar
|
|
44
|
Moreira AM, Pereira J, Melo S, Fernandes
MS, Carneiro P, Seruca R and Figueiredo J: The extracellular
matrix: An accomplice in gastric cancer development and
progression. Cells. 9:3942020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Raja UM, Gopal G, Shirley S, Ramakrishnan
AS and Rajkumar T: Immunohistochemical expression and localization
of cytokines/chemokines/growth factors in gastric cancer. Cytokine.
89:82–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chung HW and Lim JB: Role of the tumor
microenvironment in the pathogenesis of gastric carcinoma. World J
Gastroenterol. 20:1667–1680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tian Y, Xie Y, Yi G, Wu F, Dang X, Bai F,
Wang J and Zhang D: Prognostic value and therapeutic significance
of CCL chemokines in gastric cancer. Curr Med Chem. 31:7043–7058.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oya Y, Hayakawa Y and Koike K: Tumor
microenvironment in gastric cancers. Cancer Sci. 111:2696–2707.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu M, Wang Z, He Y, Zhang B, Wu L, Liu C,
Fei Y, Gao P, Cai J and Zuo X: Acidic tumor
microenvironment-modulated nanoparticle potentiates gastric cancer
photoimmunotherapy. J Adv Res. June 6–2025.(Epub ahead of
print).
|
|
50
|
Liu HY, Wang FH, Liang JM, Xiang YY, Liu
SH, Zhang SW, Zhu CM, He YL and Zhang CH: Targeting NAD metabolism
regulates extracellular adenosine levels to improve the
cytotoxicity of CD8+ effector T cells in the tumor microenvironment
of gastric cancer. J Cancer Res Clin Oncol. 149:2743–2756. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rojas A, Araya P, Gonzalez I and Morales
E: Gastric tumor microenvironment. Adv Exp Med Biol. 1226:23–35.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lin K, Lin X and Luo F: IGF2BP3 boosts
lactate generation to accelerate gastric cancer immune evasion.
Apoptosis. 29:2147–2160. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cornel AM, Mimpen IL and Nierkens S: MHC
Class I downregulation in cancer: Underlying mechanisms and
potential targets for cancer immunotherapy. Cancers (Basel).
12:17602020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Isobe T, Aoyagi K, Koufuji K, Shirouzu K,
Kawahara A, Taira T and Kage M: Clinicopathological significance of
hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric
cancer. Int J Clin Oncol. 18:293–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Balasubramanian A, John T and
Asselin-Labat ML: Regulation of the antigen presentation machinery
in cancer and its implication for immune surveillance. Biochem Soc
Trans. 50:825–837. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zong J, Keskinov AA, Shurin GV and Shurin
MR: Tumor-derived factors modulating dendritic cell function.
Cancer Immunol Immunother. 65:821–833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schmidt SV, Nino-Castro AC and Schultze
JL: Regulatory dendritic cells: There is more than just immune
activation. Front Immunol. 3:2742012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sodir NM, Pathria G, Adamkewicz JI, Kelley
EH, Sudhamsu J, Merchant M, Chiarle R and Maddalo D: SHP2: A
pleiotropic target at the interface of cancer and its
microenvironment. Cancer Discov. 13:2339–2355. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sobhani N, Tardiel-Cyril DR, Davtyan A,
Generali D, Roudi R and Li Y: CTLA-4 in regulatory T cells for
cancer immunotherapy. Cancers (Basel). 13:14402021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kandel S, Adhikary P, Li G and Cheng K:
The TIM3/Gal9 signaling pathway: An emerging target for cancer
immunotherapy. Cancer Lett. 510:67–78. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yuan XL, Chen L, Zhang TT, Ma YH, Zhou YL,
Zhao Y, Wang WW, Dong P, Yu L, Zhang YY and Shen LS: Gastric cancer
cells induce human CD4+Foxp3+ regulatory T cells through the
production of TGF-β1. World J Gastroenterol. 17:2019–2027. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen L, Shi Y, Zhu X, Guo W, Zhang M, Che
Y, Tang L, Yang X, You Q and Liu Z: IL-10 secreted by
cancer-associated macrophages regulates proliferation and invasion
in gastric cancer cells via c-Met/STAT3 signaling. Oncol Rep.
42:595–604. 2019.PubMed/NCBI
|
|
63
|
Bourhis M, Palle J, Galy-Fauroux I and
Terme M: Direct and indirect modulation of T Cells by VEGF-A
counteracted by Anti-angiogenic treatment. Front Immunol.
12:6168372021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lee WS, Yang H, Chon HJ and Kim C:
Combination of Anti-angiogenic therapy and immune checkpoint
blockade normalizes vascular-immune crosstalk to potentiate cancer
immunity. Exp Mol Med. 52:1475–1485. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ye Z, Yue L, Shi J, Shao M and Wu T: Role
of IDO and TDO in cancers and related diseases and the therapeutic
implications. J Cancer. 10:2771–2782. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Platten M, von Knebel Doeberitz N, Oezen
I, Wick W and Ochs K: Cancer Immunotherapy by Targeting IDO1/TDO
and their downstream effectors. Front Immunol. 5:6732014.PubMed/NCBI
|
|
67
|
Sosnowska A, Chlebowska-Tuz J, Matryba P,
Pilch Z, Greig A, Wolny A, Grzywa TM, Rydzynska Z, Sokolowska O,
Rygiel TP, et al: Inhibition of arginase modulates T-cell response
in the tumor microenvironment of lung carcinoma. Oncoimmunology.
10:19561432021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liang JJ, Fraser IDC and Bryant CE: Lipid
regulation of NLRP3 inflammasome activity through organelle stress.
Trends Immunol. 42:807–823. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lagunas-Rangel FA: Cholesterol effects on
the tumor immune microenvironment: From fundamental concepts to
mechanisms and implications. Front Oncol. 15:15790542025.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai
W, Li J, Liao T, Li C and He J: The epigenetic hallmarks of immune
cells in cancer. Mol Cancer. 24:662025. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Emran AA, Chatterjee A, Rodger EJ, Tiffen
JC, Gallagher SJ, Eccles MR and Hersey P: Targeting DNA Methylation
and EZH2 activity to overcome melanoma resistance to immunotherapy.
Trends Immunol. 40:328–344. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Belk JA, Daniel B and Satpathy AT:
Epigenetic regulation of T cell exhaustion. Nat Immunol.
23:848–860. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wang C, Wang X, Zhang D, Sun X, Wu Y, Wang
J, Li Q and Jiang G: The macrophage polarization by miRNAs and its
potential role in the treatment of tumor and inflammation (Review).
Oncol Rep. 50:1902023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang
CY and Zen K: Re-polarization of tumor-associated macrophages to
pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol.
4:341–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wozniak M and Czyz M: lncRNAs-EZH2
interaction as promising therapeutic target in cutaneous melanoma.
Front Mol Biosci. 10:11700262023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Su Y, Bai Q, Zhang W, Xu B and Hu T: The
role of Long Non-coding RNAs in modulating the immune
microenvironment of Triple-negative breast cancer: Mechanistic
insights and therapeutic potential. Biomolecules. 15:4542025.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y,
Yu T, Zhang L, Zhu L and Shu Y: Role of exosomal non-coding RNAs
from tumor cells and tumor-associated macrophages in the tumor
microenvironment. Mol Ther. 30:3133–3154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yang X, Zhang Y, Zhang Y, Zhang S, Qiu L,
Zhuang Z, Wei M, Deng X, Wang Z and Han J: The key role of exosomes
on the pre-metastatic niche formation in tumors. Front Mol Biosci.
8:7036402021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang
JH and Zhang SJ: Exosome biogenesis: Machinery, regulation, and
therapeutic implications in cancer. Mol Cancer. 21:2072022.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Mizukami Y, Kono K, Kawaguchi Y, Akaike H,
Kamimura K, Sugai H and Fujii H: CCL17 and CCL22 chemokines within
tumor microenvironment are related to accumulation of Foxp3+
regulatory T cells in gastric cancer. Int J Cancer. 122:2286–2293.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ren W, Zhang X, Li W, Feng Q, Feng H, Tong
Y, Rong H, Wang W, Zhang D, Zhang Z and Tu S: Circulating and
tumor-infiltrating arginase 1-expressing cells in gastric
adenocarcinoma patients were mainly immature and monocytic
Myeloid-derived suppressor cells. Sci Rep. 10:80562020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhang J, Hu C, Zhang R, Xu J, Zhang Y,
Yuan L, Zhang S, Pan S, Cao M, Qin J, et al: The role of
macrophages in gastric cancer. Front Immunol. 14:12821762023.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Baradaran A, Asadzadeh Z, Hemmat N,
Baghbanzadeh A, Shadbad MA, Khosravi N, Derakhshani A, Alemohammad
H, Afrashteh Nour M, Safarpour H, et al: The cross-talk between
tumor-associated macrophages and tumor endothelium: Recent advances
in macrophage-based cancer immunotherapy. Biomed Pharmacother.
146:1125882022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Corzo CA, Cotter MJ, Cheng P, Cheng F,
Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC and
Gabrilovich DI: Mechanism regulating reactive oxygen species in
tumor-induced myeloid-derived suppressor cells. J Immunol.
182:5693–5701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Nagaraj S, Gupta K, Pisarev V, Kinarsky L,
Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich DI: Altered
recognition of antigen is a mechanism of CD8+ T cell tolerance in
cancer. Nat Med. 13:828–835. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yamaguchi T, Fushida S, Kinoshita J,
Okazaki M, Ishikawa S, Ohbatake Y, Terai S, Okamoto K, Nakanuma S,
Makino I, et al: Extravasated platelet aggregation contributes to
tumor progression via the accumulation of myeloid-derived
suppressor cells in gastric cancer with peritoneal metastasis.
Oncol Lett. 20:1879–1887. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhou Y and Guo F: A selective
sphingosine-1-phosphate receptor 1 agonist SEW-2871 aggravates
gastric cancer by recruiting myeloid-derived suppressor cells. J
Biochem. 163:77–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kusmartsev S, Su Z, Heiser A, Dannull J,
Eruslanov E, Kübler H, Yancey D, Dahm P and Vieweg J: Reversal of
myeloid cell-mediated immunosuppression in patients with metastatic
renal cell carcinoma. Clin Cancer Res. 14:8270–8278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ren W, Zhang X, Li W, Feng Q, Feng H, Tong
Y, Rong H, Wang W, Zhang D, Zhang Z, et al: Exosomal miRNA-107
induces myeloid-derived suppressor cell expansion in gastric
cancer. Cancer Manag Res. 11:4023–4040. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Chen X, Wang Y, Wang J, Wen J, Jia X, Wang
X and Zhang H: Accumulation of T-helper 22 cells, interleukin-22
and myeloid-derived suppressor cells promotes gastric cancer
progression in elderly patients. Oncol Lett. 16:253–261.
2018.PubMed/NCBI
|
|
92
|
Gordon S and Martinez FO: Alternative
activation of macrophages: Mechanism and functions. Immunity.
32:593–604. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bronte V and Zanovello P: Regulation of
immune responses by L-arginine metabolism. Nat Rev Immunol.
5:641–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Tsutsumi C, Ohuchida K, Yamada Y, Shimada
Y, Imamura M, Son K, Mochida Y, Katayama N, Iwamoto C, Torata N, et
al: Claudin18.2-positive gastric cancer-specific changes in
neoadjuvant chemotherapy-driven immunosuppressive tumor
microenvironment. Br J Cancer. 132:793–804. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Aizaz M, Khan A, Khan F, Khan M, Musad
Saleh EA, Nisar M and Baran N: The cross-talk between macrophages
and tumor cells as a target for cancer treatment. Front Oncol.
13:12590342023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
He S, Zheng L and Qi C: Myeloid-derived
suppressor cells (MDSCs) in the tumor microenvironment and their
targeting in cancer therapy. Mol Cancer. 24:52025. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Masmoudi D, Villalba M and Alix-Panabières
C: Natural killer cells: The immune frontline against circulating
tumor cells. J Exp Clin Cancer Res. 44:1182025. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wang J, Huang H, Lu J, Bi P, Wang F, Liu
X, Zhang B, Luo Y and Li X: Tumor cells induced-M2 macrophage
favors accumulation of Treg in nasopharyngeal carcinoma. Int J Clin
Exp Pathol. 10:8389–8401. 2017.PubMed/NCBI
|
|
100
|
Mirlekar B: Tumor promoting roles of
IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer
immunotherapy. SAGE Open Med. 10:205031212110690122022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Shaopeng Z, Yang Z, Yuan F, Chen H and
Zhengjun Q: Regulation of regulatory T cells and tumor-associated
macrophages in gastric cancer tumor microenvironment. Cancer Med.
13:e69592024. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wang B, Zhang Z, Liu W and Tan B:
Targeting regulatory T cells in gastric cancer: Pathogenesis,
immunotherapy, and prognosis. Biomed Pharmacother. 158:1141802023.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ling Z, Shao L and Liu X, Cheng Y, Yan C,
Mei Y, Ji F and Liu X: Regulatory T cells and plasmacytoid
dendritic cells within the tumor microenvironment in gastric cancer
are correlated with gastric microbiota dysbiosis: A preliminary
study. Front Immunol. 10:5332019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lin Y, Jing X, Chen Z, Pan X, Xu D, Yu X,
Zhong F, Zhao L, Yang C, Wang B, et al: Histone
deacetylase-mediated tumor microenvironment characteristics and
synergistic immunotherapy in gastric cancer. Theranostics.
13:4574–4600. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hoechst B, Ormandy LA, Ballmaier M, Lehner
F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of
myeloid-derived suppressor cells in hepatocellular carcinoma
patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology.
135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Peng X, He Y, Huang J, Tao Y and Liu S:
Metabolism of dendritic cells in tumor microenvironment: For
immunotherapy. Front Immunol. 12:6134922021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chen J, Duan Y, Che J and Zhu J:
Dysfunction of dendritic cells in tumor microenvironment and
immunotherapy. Cancer Commun (Lond). 44:1047–1070. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Wang B, Gu B, Gao L, Ma C, Li X, Wang Y,
Hu J, Wang N, Xiang L, Yu Y, et al: SERPINE1 facilitates metastasis
in gastric cancer through anoikis resistance and tumor
microenvironment remodeling. Small. 21:e25001362025. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Fu C and Jiang A: Dendritic cells and CD8
T cell immunity in tumor microenvironment. Front Immunol.
9:30592018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ni L: Advances in human dendritic
Cell-based immunotherapy against gastrointestinal cancer. Front
Immunol. 13:8871892022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ghasemi M, Abbasi L, Ghanbari Naeini L,
Kokabian P, Nameh Goshay Fard N and Givtaj N: Dendritic cells and
natural killer cells: The road to a successful oncolytic
virotherapy. Front Immunol. 13:9500792022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jin J, Lin J, Xu A, Lou J, Qian C, Li X,
Wang Y, Yu W and Tao H: CCL2: An important mediator between tumor
cells and host cells in tumor microenvironment. Front Oncol.
11:7229162021. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Li Y, Zheng Y, Huang J, Nie RC, Wu QN, Zuo
Z, Yuan S, Yu K, Liang CC, Pan YQ, et al: CAF-macrophage crosstalk
in tumour microenvironments governs the response to immune
checkpoint blockade in gastric cancer peritoneal metastases. Gut.
74:350–363. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wan S, Zhao E, Kryczek I, Vatan L,
Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH:
Tumor-associated macrophages produce interleukin 6 and signal via
STAT3 to promote expansion of human hepatocellular carcinoma stem
cells. Gastroenterology. 147:1393–1404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
McRitchie BR and Akkaya B: Exhaust the
exhausters: Targeting regulatory T cells in the tumor
microenvironment. Front Immunol. 13:9400522022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Patsoukis N, Bardhan K, Chatterjee P, Sari
D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, et al:
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis
and promoting lipolysis and fatty acid oxidation. Nat Commun.
6:66922015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang Z, Ji X, Zhang Y, Yang F, Su H, Zhang
H, Li Z, Zhang W and Sun W: Interactions between LAMP3+ dendritic
cells and T-cell subpopulations promote immune evasion in papillary
thyroid carcinoma. J Immunother Cancer. 12:e0089832024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Raber P, Ochoa AC and Rodríguez PC:
Metabolism of L-arginine by myeloid-derived suppressor cells in
cancer: Mechanisms of T cell suppression and therapeutic
perspectives. Immunol Invest. 41:614–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH,
Deng K and Yang JL: Lipid metabolic reprogramming in tumor
microenvironment: From mechanisms to therapeutics. J Hematol Oncol.
16:1032023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Cascone T, McKenzie JA, Mbofung RM, Punt
S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, et al:
Increased tumor glycolysis characterizes immune resistance to
adoptive T cell therapy. Cell Metab. 27:977–987.e4. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zhang S, Lv K, Liu Z, Zhao R and Li F:
Fatty acid metabolism of immune cells: A new target of tumour
immunotherapy. Cell Death Discov. 10:392024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Osada T, Chong G, Tansik R, Hong T,
Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, et al:
The effect of anti-VEGF therapy on immature myeloid cell and
dendritic cells in cancer patients. Cancer Immunol Immunother.
57:1115–1124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Porta C, Consonni FM, Morlacchi S,
Sangaletti S, Bleve A, Totaro MG, Larghi P, Rimoldi M, Tripodo C,
Strauss L, et al: Tumor-derived prostaglandin E2 promotes p50
NF-κB-Dependent differentiation of monocytic MDSCs. Cancer Res.
80:2874–2888. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Chiu DK, Tse AP, Xu IM, Di Cui J, Lai RK,
Li LL, Koh HY, Tsang FH, Wei LL, Wong CM, et al: Hypoxia inducible
factor HIF-1 promotes myeloid-derived suppressor cells accumulation
through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun.
8:5172017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bailey CM, Liu Y, Liu M, Du X, Devenport
M, Zheng P, Liu Y and Wang Y: Targeting HIF-1α abrogates
PD-L1-mediated immune evasion in tumor microenvironment but
promotes tolerance in normal tissues. J Clin Invest.
132:e1508462022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Mou P, Ge QH, Sheng R, Zhu TF, Liu Y and
Ding K: Research progress on the immune microenvironment and
immunotherapy in gastric cancer. Front Immunol. 14:12911172023.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC,
Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al:
Nivolumab plus chemotherapy versus placebo plus chemotherapy in
patients with HER2-negative, untreated, unresectable advanced or
recurrent gastric or gastro-oesophageal junction cancer
(ATTRACTION-4): A randomised, multicentre, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 23:234–247. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Moehler M, Xiao H, Blum SI, Elimova E,
Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, et
al: Health-related quality of life with nivolumab plus chemotherapy
versus chemotherapy in patients with advanced
Gastric/Gastroesophageal junction cancer or esophageal
adenocarcinoma from CheckMate 649. J Clin Oncol. 41:5388–5399.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Satake H, Lee KW, Chung HC, Lee J,
Yamaguchi K, Chen JS, Yoshikawa T, Amagai K, Yeh KH, Goto M, et al:
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of
care chemotherapy in patients with advanced gastric or
gastroesophageal junction adenocarcinoma: Asian subgroup analysis
of KEYNOTE-062. Jpn J Clin Oncol. 53:221–229. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Shitara K, Van Cutsem E, Bang YJ, Fuchs C,
Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al:
Efficacy and safety of pembrolizumab or pembrolizumab plus
chemotherapy vs chemotherapy alone for patients with First-line,
advanced gastric cancer: The KEYNOTE-062 Phase 3 randomized
clinical trial. JAMA Oncol. 6:1571–1580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S,
Zhang M, Peng Z, Zhou J, Cao Y, et al: Claudin18.2-specific CAR T
cells in gastrointestinal cancers: Phase 1 trial interim results.
Nat Med. 28:1189–1198. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wang T, Navenot JM, Rafail S, Kurtis C,
Carroll M, Van Kerckhoven M, Van Rossom S, Schats K, Avraam K,
Broad R, et al: Identifying MAGE-A4-positive tumors for TCR T cell
therapies in HLA-A*02-eligible patients. Mol Ther Methods Clin Dev.
32:1012652024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Meyer T, Finn RS, Borad M, Mahipal A,
Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M,
et al: Phase I trial of ADP-A2AFP TCR T-cell therapy in patients
with advanced hepatocellular or gastric hepatoid carcinoma. J
Hepatol. 84:113–121. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wang F, Lau JKC and Yu J: The role of
natural killer cell in gastrointestinal cancer: Killer or helper.
Oncogene. 40:717–730. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lee HJ, Hwang SJ, Jeong EH and Chang MH:
Genetically engineered CLDN18.2 CAR-T cells expressing synthetic
PD1/CD28 fusion receptors produced using a lentiviral vector. J
Microbiol. 62:555–568. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Cai F, Zhang J, Gao H and Shen H: Tumor
microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
Eur J Haematol. 112:223–235. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Frey N and Porter D: Cytokine release
syndrome with chimeric antigen receptor T cell therapy. Biol Blood
Marrow Transplant. 25:e123–e127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Shitara K, Bang YJ, Iwasa S, Sugimoto N,
Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al:
Trastuzumab deruxtecan in previously treated HER2-Positive gastric
cancer. N Engl J Med. 382:2419–2430. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Jang JY, Kim D, Lee NK, Im E and Kim ND:
Antibody-drug conjugates powered by deruxtecan: Innovations and
challenges in oncology. Int J Mol Sci. 26:65232025. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Dong S, Wei C, Wang X, Yang X, Shen W, Li
S, Xu J, Ma Y, Bie L, Yu W and Li N: A retrospective multicenter
study on the efficacy and safety of disitamab vedotin monotherapy
versus combination with anti-PD-1 immunotherapy in advanced gastric
cancer. Sci Rep. 15:22322025. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wang Y, Gong J, Wang A, Wei J, Peng Z,
Wang X, Zhou J, Qi C, Liu D, Li J, et al: Disitamab vedotin (RC48)
plus toripalimab for HER2-expressing advanced gastric or
gastroesophageal junction and other solid tumours: A multicentre,
open label, dose escalation and expansion phase 1 trial.
EClinicalMedicine. 68:1024152024. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Yasunaga M, Manabe S, Tsuji A, Furuta M,
Ogata K, Koga Y, Saga T and Matsumura Y: Development of
Antibody-drug conjugates using DDS and molecular imaging.
Bioengineering (Basel). 4:782017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Roth JS, Guo H, Chen L, Shen M, Gbadegesin
O, Robey RW, Gottesman MM and Hall MD: Identification of
antibody-drug conjugate payloads which are substrates of
ATP-binding cassette drug efflux transporters. bioRxiv. Jul
18–2025.doi: 10.1101/2025.05.22.651305.
|
|
148
|
Moon GY, Dalkiran B, Park HS, Shin D, Son
C, Choi JH, Bang S, Lee H, Doh I, Kim DH, et al: Dual biomarker
strategies for liquid biopsy: Integrating circulating tumor cells
and circulating tumor DNA for enhanced tumor monitoring. Biosensors
(Basel). 15:742025. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Braun T, Rade M, Merz M, Klepzig H, Große
F, Fandrei D, Pham NN, Kreuz M, Kuhn CK, Kuschel F, et al:
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA
CAR T cells and GPRC5D-directed bispecific antibody. Nat Med.
31:1145–1153. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Middelburg J, Schaap G, Sluijter M, Lloyd
K, Ovcinnikovs V, Schuurman J, van der Burg SH, Kemper K and van
Hall T: Cancer vaccines compensate for the insufficient induction
of protective tumor-specific immunity of CD3 bispecific antibody
therapy. J Immunother Cancer. 13:e0103312025. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Liu X, Le Gall C, Alexander RK, Borgman E,
Balligand T and Ploegh HL: Nanobody-based bispecific antibody
engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy. Nat
Biomed Eng. Jul 16–2025.doi: 10.1038/s41551-025-01447-z (Epub ahead
of print). View Article : Google Scholar
|
|
152
|
Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R,
Zeng L, Shi J, Zhang J, Zhou P, et al: Synergistic efficacy of
simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade
in cancer therapy. J Hematol Oncol. 16:942023. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Scialpi R, Espinosa-Sotelo R, Bertran E,
Dituri F, Giannelli G and Fabregat I: New Hepatocellular carcinoma
(HCC) Primary cell cultures as models for exploring personalized
Anti-TGF-β therapies based on tumor characteristics. Int J Mol Sci.
26:24302025. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Qin F, Liu X, Chen J, Huang S, Wei W, Zou
Y, Liu X, Deng K, Mo S, Chen J, et al: Anti-TGF-β attenuates tumor
growth via polarization of tumor associated neutrophils towards an
anti-tumor phenotype in colorectal cancer. J Cancer. 11:2580–2592.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Liu Y, Li Y, Wang Y, Lin C, Zhang D, Chen
J, Ouyang L, Wu F, Zhang J and Chen L: Recent progress on vascular
endothelial growth factor receptor inhibitors with dual targeting
capabilities for tumor therapy. J Hematol Oncol. 15:892022.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Jung BK, Ko HY, Kang H, Hong J, Ahn HM, Na
Y, Kim H, Kim JS and Yun CO: Relaxin-expressing oncolytic
adenovirus induces remodeling of physical and immunological aspects
of cold tumor to potentiate PD-1 blockade. J Immunother Cancer.
8:e0007632020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Hong DS, Postow M, Chmielowski B, Sullivan
R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M,
Yeckes-Rodin H, et al: Eganelisib, a First-in-Class PI3Kγ
Inhibitor, in Patients with Advanced Solid Tumors: Results of the
Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 29:2210–2219. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Sabit H, Pawlik TM, Radwan F, Abdel-Hakeem
M, Abdel-Ghany S, Wadan AS, Elzawahri M, El-Hashash A and Arneth B:
Precision nanomedicine: Navigating the tumor microenvironment for
enhanced cancer immunotherapy and targeted drug delivery. Mol
Cancer. 24:1602025. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Kundu M, Butti R, Panda VK, Malhotra D,
Das S, Mitra T, Kapse P, Gosavi SW and Kundu GC: Modulation of the
tumor microenvironment and mechanism of Immunotherapy-based drug
resistance in breast cancer. Mol Cancer. 23:922024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Fujiwara Y, Kinoshita J, Shimada M, Saito
H, Tsuji T, Yamamoto D, Moriyama H, Horii M, Nomura S, Matsushita
T, et al: Regulatory B cells drive immune evasion in the tumor
microenvironment and are involved peritoneal metastasis in gastric
cancer. Sci Rep. 15:274992025. View Article : Google Scholar : PubMed/NCBI
|
